Factors Associated With Achieving Complete Skin Clearance Compared to Almost Complete Skin Clearance in Patients With Moderate to Severe Psoriasis Treated With Biologics: A Retrospective Chart Review
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Biologics have demonstrated high efficacy in achieving ‘almost complete’ skin clearance in patients with moderate to severe psoriasis. Nonetheless, achieving ‘complete’ skin clearance remains a treatment goal for some highly biologics-resistant patients, as residual lesions impact their quality of life. Objective: The risk factors for failure to achieve a Psoriasis Area and Severity Index (PASI) 100 response in patients with good response to biologics remain unknown. Methods: This retrospective study evaluated the risk factors by comparing patients who achieved complete skin clearance (PASI100) with those who achieved almost complete skin clearance (PASI90). A database of 131 psoriasis patients treated with biologics, who achieved a PASI90 or PASI100 response, was reviewed from a tertiar y referral hospital in South Korea. The patients were classified into PASI90 and PASI100 groups according to their PASI response. Results: The PASI100 group had a lower prevalence of smoking histor y (adjusted odds ratio [OR], 0.34; 95% confidence inter val [CI], 0.14–0.85; p=0.021) and psoriasis on the anterior lower legs at baseline (adjusted OR, 0.18; 95% CI, 0.03–0.99; p=0.049) than patients in the PASI90 group. Conclusion: This study suggested that smoking histor y and psoriatic skin lesions on the ante- rior lower legs are considered as the risk factors for the failure to achieve a PASI100 response in psoriasis patients treated with biologics.
Abstract
Background: Biologics have demonstrated high efficacy in achieving ‘almost complete’ skin clearance in patients with moderate to severe psoriasis. Nonetheless, achieving ‘complete’ skin clearance remains a treatment goal for some highly biologics-resistant patients, as residual lesions impact their quality of life. Objective: The risk factors for failure to achieve a Psoriasis Area and Severity Index (PASI) 100 response in patients with good response to biologics remain unknown. Methods: This retrospective study evaluated the risk factors by comparing patients who achieved complete skin clearance (PASI100) with those who achieved almost complete skin clearance (PASI90). A database of 131 psoriasis patients treated with biologics, who achieved a PASI90 or PASI100 response, was reviewed from a tertiar y referral hospital in South Korea. The patients were classified into PASI90 and PASI100 groups according to their PASI response. Results: The PASI100 group had a lower prevalence of smoking histor y (adjusted odds ratio [OR], 0.34; 95% confidence inter val [CI], 0.14–0.85; p=0.021) and psoriasis on the anterior lower legs at baseline (adjusted OR, 0.18; 95% CI, 0.03–0.99; p=0.049) than patients in the PASI90 group. Conclusion: This study suggested that smoking histor y and psoriatic skin lesions on the ante- rior lower legs are considered as the risk factors for the failure to achieve a PASI100 response in psoriasis patients treated with biologics.
참고문헌 (45)
- Parisi R, "National, regional, and worldwide epidemiology of pso¬riasis : systematic analysis and modelling study", BMJ, 369, pp.m1590~ (2020)
- Boehncke WH, "Psoriasis", Lancet, 386, pp.983~994 (2015)
- Mattei PL, "Psoriasis Area Severity Index(PASI)and the Dermatology Life Quality Index(DLQI) : the correlation between disease severity and psychological burden in patients treated with biological therapies", J Eur Acad Dermatol Venereol, 28, pp.333~337 (2014)
- Elewski BE, "Psoriasis patients with psoriasis Area and Severity Index(PASI)90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response : results from two phase 3 studies of secukinumab", J Dermatolog Treat, 28, pp.492~499 (2017)
- Puig L, "PASI90 response : the new standard in therapeutic efficacy for psoriasis", J Eur Acad Dermatol Venereol, 29, pp.645~648 (2015)
- Brown G, "Anti-IL-17 phase II data for psoriasis : a review", J Dermatolog Treat, 26, pp.32~36 (2015)
- Langley RG, "Secukinumab in plaque psoriasis--results of two phase 3 trials", N Engl J Med, 371, pp.326~338 (2014)
- Blauvelt A, "Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis : results from the phase III, double-blinded, placebo-and active comparator-controlled VOYAGE 1 trial", J Am Acad Dermatol, 76, pp.405~417 (2017)
- Belinchón Romero I, "PASI 100 response rates in moderate to severe psoriasis : a systematic literature review and analysis of clinical practice guidelines", J Dermatolog Treat, 33, pp.1661~1669 (2022)
- Lacour JP, "Association between patient-and physician-reported outcomes in patients with moderate-to-severe plaque Psoriasis Treated with Biologics in Real Life(PSO-BIO-REAL)", Dermatol Ther(Heidelb), 10, pp.1099~1109 (2020)
- Strober B, "Clinical meaningfulness of complete skin clearance in psoriasis", J Am Acad Dermatol, 75, pp.77~82 (2016)
- Viswanathan HN, "Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis", J Dermatolog Treat, 26, pp.235~239 (2015)
- Revicki DA, "Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis", Dermatology, 216, pp.260~270 (2008)
- Takeshita J, "Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting", J Am Acad Dermatol, 71, pp.633~641 (2014)
- Feldman SR, "Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice", J Dermatolog Treat, 27, pp.224~227 (2016)
- Loft N, "Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment : a nationwide study", J Eur Acad Dermatol Venereol, 36, pp.1284~1291 (2022)
- Zhou H, "Impact of smoking on psoriasis risk and treatment efficacy : a meta-analysis", J Int Med Res, 48, pp.300060520964024~ (2020)
- Karczewski J, "Factors affecting response to biologic treatment in psoriasis", Dermatol Ther, 27, pp.323~330 (2014)
- Chen L, "HLA-Cw6 and psoriasis", Br J Dermatol, 178, pp.854~862 (2018)
- Mourad A, "Factors predicting persistence of biologic drugs in psoriasis : a systematic review and meta-analysis", Br J Dermatol, 181, pp.450~458 (2019)
- Edson-Heredia E, "Heterogeneity of response to biologic treatment : perspective for psoriasis", J Invest Dermatol, 134, pp.18~23 (2014)
- Iskandar IY, "Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender", Br J Dermatol, 184, pp.243~258 (2021)
- Gkalpakiotis S, "Risankizumab for the treatment of moderate-to-severe psoriasis: real-life multicenter experience from the Czech Republic", Dermatol Ther(Heidelb), 11, pp.1345~1355 (2021)
- Warren RB, "Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis : a multicentre longitudinal cohort study", Br J Dermatol, 180, pp.1069~1076 (2019)
- Mastorino L, "Risankizumab shows high efficacy and maintenance in improvement of response until week 52", Dermatol Ther, 35, pp.e15378~ (2022)
- Xie KK, "Baseline patients’ characteristics as predictors for therapeutic survival and response in patients with pso¬riasis on biological treatments", Australas J Dermatol, 59, pp.e247~e252 (2018)
- Schwarz CW, "Predictors of response to biologics in patients with moderate-to-severe psoriasis : a Danish nationwide cohort study", Acta Derm Venereol, 101, pp.adv00579~ (2021)
- Zweegers J, "Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice : results from the prospective, multicenter BioCAPTURE cohort", Br J Dermatol, 176, pp.786~793 (2017)
- Hansel K, "A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis", J Eur Acad Dermatol Venereol, 36, pp.e111~e113 (2022)
- Hansel K, "A multicenter study on effectiveness and safety of risankizumab in psoriasis : an Italian 16-week real-life experience during the COVID-19 pandemic", J Eur Acad Dermatol Venereol, 35, pp.e169~e170 (2021)
- Yanaba K, "Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis : a retrospective cohort study of 111 patients", Arch Dermatol Res, 306, pp.921~925 (2014)
- Talamonti M, "High-resolution HLA typing identifies a new ‘super re¬sponder’ subgroup of HLA-C*06 : 02-positive psoriatic patients : HLA-C*06 : 02", HLA-C*04, in response to ustekinumab, 2019, pp.33, e364~e367
- Kwon SH, "Secukinumab response in Korean patients with moderate to severe plaque-type psoriasis irrespective of previous biologic use : 1-year experience at a single center", Ann Dermatol, 32, pp.255~257 (2020)
- Pinter A, "Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis", J Dermatolog Treat, 31, pp.769~775 (2020)
- WHO Expert Consultation, "Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies", Lancet, 363, pp.157~163 (2004)
- Armstrong AW, "Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms", Br J Dermatol, 165, pp.1162~1168 (2011)
- Bardazzi F, "The legs : an underestimated difficult-to-treat area of psoriasis", Der¬matol Ther, 35, pp.e15485~ (2022)
- Muslimani MA, "Psoriatic patients undergoing long-term therapy with biologics : Impact of residual localization of psoriasis on quality of life in an Italian clinical setting", Dermatol Ther, 33, pp.e14337~ (2020)
- Hjuler KF, "Localization of treatment-resistant areas in patients with psoriasis on biologics", Br J Dermatol, 181, pp.332~337 (2019)
- Won SH, "Which areas are still left in biologics responsive Korean patients with moderate to severe plaque psoriasis", Ann Dermatol, 35, pp.6~10 (2023)
- Son SW, "Differences in clinical responses to ustekinumab treatment among body regions: results from a real-world prospective, observational, and multi-center study in Korea", Ann Dermatol, 34, pp.14~21 (2022)
- Singh S, "Induction of psoriasis and Koebner’s phenomenon", J Dermatol, 37, pp.568~569 (2010)
- Matos TR, "Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing αβ T cell clones", J Clin Invest, 127, pp.4031~4041 (2017)
- Fülle M, "Psoriasis on the leg : site-specific histopathological and immuno-histochemical features and diagnostic difficulties", Acta Derm Venereol, 101, pp.adv00453~ (2021)
- Carrera CG, "PACE study : real-life Psoriasis Area and Severity Index(PASI)100 response with biological agents in moderate-severe psoriasis", J Dermatolog Treat, 29, pp.481~486 (2018)